crohn's disease and glp-1 semaglutide New research published in the Foundation's journal Crohn's & Colitis 360 found Recommendations for the safe and

Widely used for type 2 diabetes mellitus and obesity, glucagon-like peptide-1 receptor agonists (GLP-1RAs) may increase risk for injection-site reactions, especially exenatide and dulaglutide (Trulicity, Eli Lilly)

Home Medical news & Guidelines Anesthesiology Cardiology and CTVS Critical Care Dentistry Dermatology Diabetes and Endocrinology ENT Gastroenterology Medicine Nephrology Neurology Obstretics-Gynaecology Oncology Ophthalmology Orthopaedics Pediatrics-Neonatology Psychiatry Pulmonology Radiology Surgery Urology Laboratory Medicine Diet Nursing Paramedical Physiotherapy Health news Fact Check Bone Health Fact Check Brain Health Fact Check Cancer Related Fact Check Child Care Fact Check Dental and oral health fact check Diabetes and metabolic health fact check Diet and Nutrition Fact Check Eye and ENT Care Fact Check Fitness fact check Gut health fact check Heart health fact check Kidney health fact check Medical education fact check Men's health fact check Respiratory fact check Skin and hair care fact check Vaccine and Immunization fact check Women's health fact check AYUSH State News Andaman and Nicobar Islands Andhra Pradesh Arunachal Pradesh Assam Bihar Chandigarh Chattisgarh Dadra and Nagar Haveli Daman and Diu Delhi Goa Gujarat Haryana Himachal Pradesh Jammu & Kashmir Jharkhand Karnataka Kerala Ladakh Lakshadweep Madhya Pradesh Maharashtra Manipur Meghalaya Mizoram Nagaland Odisha Puducherry Punjab Rajasthan Sikkim Tamil Nadu Telangana Tripura Uttar Pradesh Uttrakhand West Bengal Medical Education Industry Metformin in Weight Loss Maintenance: A Possible Opportunity Post-GLP-RA Discontinuation?- Dr

Abushanab et al

How to Stay Healthy While Using GLP-1s 1

The dose should be individualized based on response, tolerability, safety, nutrition, body composition, and clinical goals

Figure S3: (A) Individual study result of primary outcome: incidence of hearing loss, (B) Individual study result of primary outcome: incidence of hearing loss in subgroup of dosage, (C) Individual study result of drop-out rate